NEJM has published Phase II data for retatrutide (Jastreboff et al, June 2023, doi 10.1056/NEJMoa2301972) and the SURPASS and SURMOUNT programmes for tirzepatide
Check with your insurance company to see if they cover Mounjaro
As a GLP-1 (glucagon-like peptide-1) receptor agonist, Ozempic stands out from other medications in its class due to several unique characteristics that directly benefit our patients
Afamelanotide, via Scenesse, benefits from a well-characterized safety profile in EPP therapeutic use: controlled cutaneous hyperpigmentation, rare digestive effects, no major cardiovascular signal
Where available, fold differences were calculated from total curcumin plasma levels, and from the AUC for the longest defined time period
These effects are usually short-lived